Analysts' Actions -- Alnylam, AutoNation, Tesla and More
RATINGS CHANGES
Alnylam (ALNY) - Get Alnylam Pharmaceuticals, Inc Report was downgraded to equal-weight from overweight at Barclays. $50 price target. The company has seen multiple pipeline setbacks, Barclays said.
Alnylam was downgraded to neutral from overweight at JPMorgan. $51 price target. Revusiran blow is a big hit to the company's potential growth, JPMorgan said.
Alnylam was downgraded to market perform at Leerink Partners. $40 price target. Revusiran failure adds risk to the company's clinical pipeline, Leerink said.
AutoNation (AN) - Get AutoNation, Inc. Report was upgraded to neutral from sell at Goldman Sachs. $49 price target. The valuation is more attractive, as the stock has trailed the market by 15% over the past seven months, Goldman said.
American Express (AXP) - Get American Express Company Report was downgraded to reduce from neutral at Nomura. $56 price target. The company will likely continue to lose market share and miss revenue expectations, Nomura said.
TheStreet Recommends
GigPeak (GIG) - Get GigCapital4, Inc. Report was upgraded to buy at TheStreet Ratings. You can view the full analysis from the report here: GIG.
Imperva (IMPV) - Get Imperva, Inc. Report was downgraded to neutral from buy at DA Davidson. $55 price target. Despite potential acquisition, there appears to be little upside to valuation, Davidson said.
Ionis (IONS) - Get Ionis Pharmaceuticals, Inc. Report was upgraded to outperform at BMO Capital. $48 price target. The company should benefit from pain at competitor Alnylam, BMO said.
Moog (MOG.A) - Get Moog Inc. Class A Report was downgraded to hold at TheStreet Ratings. You can view the full analysis from the report here: MOG.A.
Tesla (TSLA) - Get Tesla Inc Report was downgraded to neutral from buy at Goldman Sachs. $185 price target. Acquisition adds risk to the model and leaves little room for potential production delays, Goldman said.
This article was written by a staff member of TheStreet.
